Purdue Pharma LP
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1892-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.purduepharma.com
Pharmacodynamic Evaluation of Intramuscular Nalmefene Autoinjector 1.5 mg Compared to Intranasal Narcan 4 mg
- Conditions
- Interventions
- First Posted Date
- 2024-12-06
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 27
- Registration Number
- NCT06719986
- Locations
- 🇺🇸
Ohio Clinical Trials, Columbus, Ohio, United States
Clinical Outcomes From Nalmefene
- Conditions
- Interventions
- First Posted Date
- 2023-04-12
- Last Posted Date
- 2023-07-12
- Lead Sponsor
- Purdue Pharma LP
- Registration Number
- NCT05808881
Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 103
- Registration Number
- NCT04987762
- Locations
- 🇺🇸
iResearch Atlanta, LLC, Decatur, Georgia, United States
🇺🇸Family Psychiatry of the Woodlands, The Woodlands, Texas, United States
🇺🇸Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States
Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)
- Conditions
- Interventions
- First Posted Date
- 2020-08-11
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 267
- Registration Number
- NCT04507204
- Locations
- 🇺🇸
Neurobehavioral Medicine Group, Bloomfield Hills, Michigan, United States
🇺🇸InSite Clinical Research, LLC, DeSoto, Texas, United States
🇺🇸Rochester Center for Behavioral Medicine, Rochester Hills, Michigan, United States
Effect of Wearable Health Technology on Patients Treated for Chronic Pain at Geisinger Health System
- First Posted Date
- 2017-10-03
- Last Posted Date
- 2019-12-16
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 135
- Registration Number
- NCT03299556
- Locations
- 🇺🇸
Geisinger Health System, Danville, Pennsylvania, United States
A Study to Evaluate the Analgesic Efficacy and Safety of V120083 in Subjects With Osteoarthritis (OA) of the Knee
- First Posted Date
- 2017-01-23
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 291
- Registration Number
- NCT03028870
- Locations
- 🇺🇸
New Horizon Research Center, Miami, Florida, United States
🇺🇸New Horizons Clinical Research, Cincinnati, Ohio, United States
🇺🇸Diagnostics Research Group, San Antonio, Texas, United States
A Study to Evaluate the Analgesic Efficacy and Safety of VM902A in Subjects With Osteoarthritis (OA) of the Knee
- Conditions
- Interventions
- First Posted Date
- 2016-07-28
- Last Posted Date
- 2017-11-22
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 75
- Registration Number
- NCT02847702
- Locations
- 🇺🇸
Investigational Site, South Jordan, Utah, United States
Experimental Biomarker Study for Pain Thresholds
- Conditions
- Interventions
- First Posted Date
- 2016-03-01
- Last Posted Date
- 2016-03-01
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 37
- Registration Number
- NCT02695745
- Locations
- 🇩🇰
CCBR A/S, Aalborg, Denmark
Safety, Pharmacokinetics (PK), and Effectiveness of Hydrocodone Bitartrate (HYD) Extended-Release Tablets in Children
- First Posted Date
- 2015-09-04
- Last Posted Date
- 2017-04-24
- Lead Sponsor
- Purdue Pharma LP
- Registration Number
- NCT02542098
The Effect of Hydrocodone Bitartrate (HYD) Extended-Release Tablets on QT /QTc Intervals in Healthy Adult Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2014-09-17
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 208
- Registration Number
- NCT02243241
- Locations
- 🇺🇸
PPD Phase I Clinic, Austin, Texas, United States